RxDoctor Payments Data

Brinda Emu, MD

Infectious Disease · New Haven, CTNPI 1245328509

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,713 of the $18,257 with a category attached, or 64.2%. Theratechnologies Inc. accounts for 70.2% of it on its own, with 4 other manufacturers making up the rest. 2024 is the largest year on record at $8,566, more than ten times the $12 reported in 2019. Among infectious disease clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,257in general payments, 2019–2025

Across 36 payments — averaging $507.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Theratechnologies Inc.$13K
  • Genentech, Inc.$2K
  • Merck$2K
  • Gilead$870
  • Roche Molecular Systems, Inc.$12
$147,363in research payments, 2019–2025

Across 19 payments — averaging $7755.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Theratechnologies Inc.$136K
  • Merck$12K

What the payments were for

  • Consulting fees$11,71364%
  • Speaking & faculty fees$750%
  • Travel & lodging$5,52030%
  • Food & beverage$7554%
  • Education$1951%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Theratechnologies Inc.17$12,821
Genentech, Inc.2$2,373
Merck14$2,182
Gilead2$870
Roche Molecular Systems, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,257 in reported general payments places this provider in the 90th percentile of 159 infectious disease providers in Connecticut.

See all infectious disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$18,151
Medicare patients
53
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →